Endosomal proteases influence the repertoire of MAGE-A3 epitopes recognized in vivo by CD4+ T cells

Jill Marturano, Renato Longhi, Vincenzo Russo, Maria Pia Protti

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Little is known about the repertoire of MAGE-A3 CD4+ T-cell epitopes recognized in vivo by neoplastic patients and how antigen processing influences epitope formation. Here, we first show that MAGE-A3-specific CD4 + T cells are present in the blood of advanced melanoma patients. MAGE-A3111-125, MAGE-A3191-205, and MAGE- A3 281-300 were recognized by 7, 6, and 5 of the 11 patients tested, respectively. MAGE-A3146-160 and MAGE-A3171-185 were also recognized in two and one cases, whereas no recognition of MAGE-A3 161-175 and MAGE- A3243-258 was observed. Cytokines produced were mainly interleukin 5 and/or granulocyte macrophage colony-stimulating factor, suggesting impairment of productive polarized Th1 responses. Secondly, proteases inhibitors were used to modulate in vitro the recognition by CD4+ T-cells clones of dendritic cells loaded with MAGE-A3-expressing cell lysates. We found that formation of MAGE-A3 111-125 depended on both leupeptin-sensitive and pepstatin-sensitive proteases. In contrast, we found that MAGE-A3161-175, which was never recognized ex vivo, was formed by leupeptin but destroyed by pepstatin-sensitive proteases. Collectively, our results show that (a) anti-MAGE-A3 CD4+ T-cell immunity develops in vivo in neoplastic patients and is focused toward immunodominant epitopes, (b) the response in advanced disease is skewed toward a Th2 type, and (c) endosomal/lysosomal proteases in dendritic cells influence the repertoire of the epitopes recognized.

Original languageEnglish
Pages (from-to)1555-1562
Number of pages8
JournalCancer Research
Volume68
Issue number5
DOIs
Publication statusPublished - Mar 1 2008

Fingerprint

Epitopes
Peptide Hydrolases
T-Lymphocytes
Dendritic Cells
Immunodominant Epitopes
T-Lymphocyte Epitopes
Interleukin-5
Antigen Presentation
Granulocyte-Macrophage Colony-Stimulating Factor
Protease Inhibitors
Immunity
Melanoma
Clone Cells
Cytokines
pepstatin
leupeptin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Endosomal proteases influence the repertoire of MAGE-A3 epitopes recognized in vivo by CD4+ T cells. / Marturano, Jill; Longhi, Renato; Russo, Vincenzo; Protti, Maria Pia.

In: Cancer Research, Vol. 68, No. 5, 01.03.2008, p. 1555-1562.

Research output: Contribution to journalArticle

@article{0954905c0d234115a59485f718a3243b,
title = "Endosomal proteases influence the repertoire of MAGE-A3 epitopes recognized in vivo by CD4+ T cells",
abstract = "Little is known about the repertoire of MAGE-A3 CD4+ T-cell epitopes recognized in vivo by neoplastic patients and how antigen processing influences epitope formation. Here, we first show that MAGE-A3-specific CD4 + T cells are present in the blood of advanced melanoma patients. MAGE-A3111-125, MAGE-A3191-205, and MAGE- A3 281-300 were recognized by 7, 6, and 5 of the 11 patients tested, respectively. MAGE-A3146-160 and MAGE-A3171-185 were also recognized in two and one cases, whereas no recognition of MAGE-A3 161-175 and MAGE- A3243-258 was observed. Cytokines produced were mainly interleukin 5 and/or granulocyte macrophage colony-stimulating factor, suggesting impairment of productive polarized Th1 responses. Secondly, proteases inhibitors were used to modulate in vitro the recognition by CD4+ T-cells clones of dendritic cells loaded with MAGE-A3-expressing cell lysates. We found that formation of MAGE-A3 111-125 depended on both leupeptin-sensitive and pepstatin-sensitive proteases. In contrast, we found that MAGE-A3161-175, which was never recognized ex vivo, was formed by leupeptin but destroyed by pepstatin-sensitive proteases. Collectively, our results show that (a) anti-MAGE-A3 CD4+ T-cell immunity develops in vivo in neoplastic patients and is focused toward immunodominant epitopes, (b) the response in advanced disease is skewed toward a Th2 type, and (c) endosomal/lysosomal proteases in dendritic cells influence the repertoire of the epitopes recognized.",
author = "Jill Marturano and Renato Longhi and Vincenzo Russo and Protti, {Maria Pia}",
year = "2008",
month = "3",
day = "1",
doi = "10.1158/0008-5472.CAN-07-5233",
language = "English",
volume = "68",
pages = "1555--1562",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Endosomal proteases influence the repertoire of MAGE-A3 epitopes recognized in vivo by CD4+ T cells

AU - Marturano, Jill

AU - Longhi, Renato

AU - Russo, Vincenzo

AU - Protti, Maria Pia

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Little is known about the repertoire of MAGE-A3 CD4+ T-cell epitopes recognized in vivo by neoplastic patients and how antigen processing influences epitope formation. Here, we first show that MAGE-A3-specific CD4 + T cells are present in the blood of advanced melanoma patients. MAGE-A3111-125, MAGE-A3191-205, and MAGE- A3 281-300 were recognized by 7, 6, and 5 of the 11 patients tested, respectively. MAGE-A3146-160 and MAGE-A3171-185 were also recognized in two and one cases, whereas no recognition of MAGE-A3 161-175 and MAGE- A3243-258 was observed. Cytokines produced were mainly interleukin 5 and/or granulocyte macrophage colony-stimulating factor, suggesting impairment of productive polarized Th1 responses. Secondly, proteases inhibitors were used to modulate in vitro the recognition by CD4+ T-cells clones of dendritic cells loaded with MAGE-A3-expressing cell lysates. We found that formation of MAGE-A3 111-125 depended on both leupeptin-sensitive and pepstatin-sensitive proteases. In contrast, we found that MAGE-A3161-175, which was never recognized ex vivo, was formed by leupeptin but destroyed by pepstatin-sensitive proteases. Collectively, our results show that (a) anti-MAGE-A3 CD4+ T-cell immunity develops in vivo in neoplastic patients and is focused toward immunodominant epitopes, (b) the response in advanced disease is skewed toward a Th2 type, and (c) endosomal/lysosomal proteases in dendritic cells influence the repertoire of the epitopes recognized.

AB - Little is known about the repertoire of MAGE-A3 CD4+ T-cell epitopes recognized in vivo by neoplastic patients and how antigen processing influences epitope formation. Here, we first show that MAGE-A3-specific CD4 + T cells are present in the blood of advanced melanoma patients. MAGE-A3111-125, MAGE-A3191-205, and MAGE- A3 281-300 were recognized by 7, 6, and 5 of the 11 patients tested, respectively. MAGE-A3146-160 and MAGE-A3171-185 were also recognized in two and one cases, whereas no recognition of MAGE-A3 161-175 and MAGE- A3243-258 was observed. Cytokines produced were mainly interleukin 5 and/or granulocyte macrophage colony-stimulating factor, suggesting impairment of productive polarized Th1 responses. Secondly, proteases inhibitors were used to modulate in vitro the recognition by CD4+ T-cells clones of dendritic cells loaded with MAGE-A3-expressing cell lysates. We found that formation of MAGE-A3 111-125 depended on both leupeptin-sensitive and pepstatin-sensitive proteases. In contrast, we found that MAGE-A3161-175, which was never recognized ex vivo, was formed by leupeptin but destroyed by pepstatin-sensitive proteases. Collectively, our results show that (a) anti-MAGE-A3 CD4+ T-cell immunity develops in vivo in neoplastic patients and is focused toward immunodominant epitopes, (b) the response in advanced disease is skewed toward a Th2 type, and (c) endosomal/lysosomal proteases in dendritic cells influence the repertoire of the epitopes recognized.

UR - http://www.scopus.com/inward/record.url?scp=40449103289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40449103289&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-5233

DO - 10.1158/0008-5472.CAN-07-5233

M3 - Article

VL - 68

SP - 1555

EP - 1562

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 5

ER -